NCT07342478 ROCKET-CLL Global Phase 3 Study: Rocbrutinib vs Pirtobrutinib in cBTKi-Pretreated R/R CLL/SLL Status RECRUITING Phase PHASE3
NCT07120633 Anti CD19 CAR-T Combined With BTKi to Treat Newly Diagnosed High-risk CLL/SLL Status RECRUITING Phase NA
NCT07108998 Study of Epcoritamab as a Consolidation Therapy in CLL/SLL Status RECRUITING Phase PHASE2
NCT05947851 A Study of Nemtabrutinib Plus Venetoclax vs Venetoclax + Rituximab (VR) in Second-line (2L) + Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) (MK-1026-010/BELLWAVE-010). Status RECRUITING Phase PHASE3
NCT04806035 Study of TG-1801 Alone or in Combination With Ublituximab in Subjects With B-Cell Lymphoma or Chronic Lymphocytic Leukemia Status TERMINATED Phase PHASE1
NCT04704323 CAP-100 for Subjects With Relapsed/Refractory Chronic Lymphocytic Leukemia Status RECRUITING Phase PHASE1
NCT04694560 A Time-Limited Approach to Treatment With Ibrutinib for Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma Status WITHDRAWN Phase N/A
NCT03639324 Rituximab, Idelalisib, and Venetoclax in Relapsed/Refractory CLL/SLL Status WITHDRAWN Phase PHASE1
NCT03572634 Phase 1/2 Study of TP-0903 (an Inhibitor of AXL Kinase) in Patients With Previously Treated CLL Status TERMINATED Phase PHASE1/PHASE2
NCT02046928 Safety, Tolerability and Efficacy of A6 in Patients With Chronic Lymphocytic Leukemia (CLL) Status TERMINATED Phase PHASE2
NCT01465334 Ofatumumab With High Dose Methylprednisone Followed by Ofatumumab and Alemtuzumab in 17p CLL Status TERMINATED Phase PHASE2
NCT00980395 Bortezomib, Cladribine, and Rituximab in Treating Patients With Advanced Mantle Cell Lymphoma or Indolent Lymphoma Status COMPLETED Phase PHASE2
NCT00546793 Ph I/II Study of Subcutaneously Administered Veltuzumab (hA20) in NHL and CLL Status COMPLETED Phase PHASE1/PHASE2